| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V97196 | ADC Control Human IgG1-Deruxtecan (DAR 8) | ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that serves as an isotype control for the ADC Human IgG1-Deruxtecan, which inhibits DNA topoisomerase I. | |
|
V103649 | ADC Control human IgG1-DM1 | ADC Control Human IgG1-DM1 is an ADC control consisting of human IgG1 kappa, isotype control, and linker-drug conjugate SMCC-DM1. | |
|
V103949 | ADC Control Human IgG1-DM4 | ADC Control Human IgG1-DM4 is the isotype control of ADC Human IgG1-DM4. The antibody part is Human IgG1 kappa, isotype control, and the ADC virulence molecule and linker part are SPDB-DM4. | |
|
V104022 | ADC Control Human IgG1-McMMAF | ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) composed of the ADC antibody IgG1 human IgG1 kappa, isotype control, and payload McMMAF. | |
|
V103948 | ADC Control Human IgG1-SN-38 | ADC Control Human IgG1-SN-38 is an isotype control for ADC Human IgG1-SN-38. | |
|
V116955 | ADC Control Human IgG1-sulfo-SPDB-DM4 | ADC Control Human IgG1-sulfo-SPDB-DM4 is an antibody-drug conjugate (ADC) that inhibits microtubule polymerization. | |
|
V117122 | ADC Control Human IgG1-tirumotecan | ADC reference standard human IgG1-tirumotecan is an antibody-drug conjugate (ADC). | |
|
V94359 | Anti-CD22-NMS249 | Anti-CD22-NMS249 is a CD22-targeting antibody-drug conjugate (ADC) composed of the humanized anti-CD22 antibody Pinatuzumab, a cleavable linker (Mc-VC-PAB), and a DNA topoisomerase II inhibitor. | |
|
V119061 | BB-1701 | BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). | |
|
V103951 | BL-B01D1 | BL-B01D1 is a bispecific ADC that targets EGFR and HER3 through the bispecific antibody Izalontamab and inhibits DNA replication and DNA synthesis through its ADC toxin ED04, exhibiting cytotoxicity against a variety of cancer cells. | |
|
V104014 | Calotatug ginistinag | 2847102-44-5 | Calotatug ginistinag (XMT-2056) is a HER2-targeting antibody-drug conjugate linked to a payload consisting of a linker (XMT-1519 conjugate-1) and a STING agonist (STING agonist-20) with potential immune-activating and anti-tumor activities. |
|
V118385 | DS-3939a | DS-3939a (DS-3939) is an antibody-drug conjugate (ADC) targeting TA-MUC1. | |
|
V117291 | Emiltatug ledadotin | 2855974-40-0 | Emiltatug ledadotin (Emi-Le; XMT-1660) is an antibody-drug conjugate (ADC) that targets B7-H4. |
|
V78751 | Exatecan Intermediate 3 | Exatecan Intermediate 3 is the intermediate of Exatecan. | |
|
V94122 | FZ-AD005 | FZ-AD005 is a DLL3-targeted ADC containing a novel anti-DLL3 antibody, FZ-A038, and a valine-alanine (Val-Ala) dipeptide linker. | |
|
V118377 | HLX43 | HLX43 is an antibody-drug conjugate (ADC) that targets PD-L1. | |
|
V76158 | Izeltabart (IMGC-936) | 2642078-60-0 | Izeltabart (IMGC-936) is a Maytansinoid-based ADC targeting ADAM9. |
|
V53069 | KRAS degrader-1 | 2795275-59-9 | KRAS degrader-1 (compound 1) is a potent KRAS degrader. |
|
V115111 | MEDI4276 | MEDI4276 is a double-chain tetravalent antibody that targets two non-overlapping epitopes in the extracellular domains 2 and 4 of HER2. | |
|
V114499 | Mirzotamab clezutoclax | 2229859-12-3 | Mirzotamab clezutoclax (ABBV-155) is a first-in-class antibody-drug conjugate (ADC) consisting of three components: an anti-B7-H3 monoclonal antibody and a BCL2L1 (BCL-XL) inhibitor, clezutoclaxum. |